NCT01879683View on ClinicalTrials.gov

A Safety, Tolerability and Preliminary Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis (IC) and Hunner's Lesions

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

June 30, 2014

Conditions
Chronic Interstitial Cystitis
Interventions
DRUG

LiRIS® 400 mg

LiRIS® 400 mg is a drug-device combination product which is placed in the bladder during cystoscopy, remains in the bladder for up to 14 days gradually releasing lidocaine, and removed from the bladder via cystoscopy.

Trial Locations (2)

32114

Advance Urology Institute, Daytona Beach

48073

William Beaumont Hospital, Royal Oak

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
collaborator

TARIS Biomedical, Inc.

INDUSTRY

lead

Allergan

INDUSTRY